Defect technology: a new horizon in endothelium transplantation

Article

Gene defect technology can be used to prevent corneal allograft rejection and the decay of endothelial cells in ex vivo corneal transplantation.

Gene defect technology can be used to prevent corneal allograft rejection and the decay of endothelial cells in ex vivo corneal transplantation, according to Dr Frank Larkin of Moorfields Eye Hospital in London, UK, presenting at the "Endothelium: new surgical and medical concepts" symposium.

Dr Larkin set out to evaluate the use of defect approaches in corneal endothelial function, and how this can aid successful cornea transplantation. After the success of a recent study in which he used this technology to carry out corneal endothelial transplantation in a donor rabbit eye, Larkin believes this approach is now "on the horizon and not over the horizon."

As a result of his studies, Dr Larkin found that using gene defect technology to create genetically engineered endothelium may help to prevent corneal allograft rejection and the decay of cells in ex vivo corneal endothelium transfer. "This is evidence that this kind of approach is biologically effective," he said.

Larkin points out that further research needs to be done to determine the longer term outcomes of this approach, "because if we want to use this in humans, it is very important that we establish the safety aspects and tolerability of this technology."

For Larkin, the future of defect technology is "on the horizon, not over it," with far-reaching possibilities for the future. "I'm quite sure that somewhere down the track this type of technology will be used in combination approaches, possibly combining cell replication with immunoprotection," he suggested, "and the earliest application will probably be in eye banking."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
© 2025 MJH Life Sciences

All rights reserved.